Bionovo expects to grant its underwriters a 30-day option to purchase up to 1.71 million shares at the public offering price to cover over-allotments, if any.
BMO Capital Markets and Canaccord Adams are acting as joint book-running managers for the proposed offering, with Merriman Curhan Ford acting as a co-manager.